For the MYC + DLBCL patients, four patients out of 23 patients (17.4%) showed increased lesional uptake, and two patients (8.7%) showed increased lesional MTV at I-PET compared to baseline (Table 5). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.